Helus Pharma Drops Despite Strong Phase 3 Depression Data as Safety Events Draw Scrutiny
Positive Phase 3 results for Helus Pharma’s HLP003 failed to support the stock, which fell amid safety concerns and a wider Q2 loss.
Already have an account? Sign in.